A pharmacodynamics study of an intravitreal amphotericin B drug delivery system for the treatment of experimental Aspergillus fumigatus endophthalmitis

Chinese Journal of Ophthalmology

Volumn 43, Issue 6, 2007, Pages 546-553

  Yang, Xia ^a   Dong, Xiao Guang ^a   Liu, Ai Ming ^a   Sun, Shi Ying ^a   Xie, Li Xin ^a   Wang, Shen Guo ^a  

^a SHANDONG EYE INSTITUTE   (China)

Author keywords

Amphotericin B; Aspergillus fumigatus; Drug delivery systems; Endophthalmitis; Eye infections; Fungal

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT;

ANIMAL; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; DRUG DELIVERY SYSTEM; ENDOPHTHALMITIS; MICROBIOLOGY; RABBIT;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; DRUG DELIVERY SYSTEMS; ENDOPHTHALMITIS; RABBITS;

EID: 34547862770     PISSN: 04124081     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Narang S, Gupta A, Gupta V, et al. Fungal endophthalmitis following cataract surgery: clinical presentation, microbiological spectrum, and outcome. Am J Ophthalmol, 2001, 132:609-617.
2. Chineses source.
3. Weishaar PD, Flynn HW Jr, Murray TG, et al. Endogenous Aspergillus endophthalmitis. Clinical features and treatment outcomes. Ophthalmology, 1998, 105: 57-65.
4. Schiedler V, Scott IU, Flynn HW Jr, et al. Culture-proven endogenous endophthalmitis: clinical features and visual acuity outcomes. Am J Ophthalmol, 2004,137:725-731.
5. Dursun D, Fernandez V, Miller D, et al. Advanced fusarium keratitis progressing to endophthalmitis. Cornes, 2003, 22:300-303.
6. Manzouri B, Vafidis GC, Wyse RK, et al. Pharmacotherapy of fungal eye infections. Expert Opin Pharmacother, 2001,2: 1849-1857.
7. Sunaric-Mégevand G, Poumaras CJ. Current approach to postoperative endophthalmitis. Br J Ophthalmol, 1997, 81: 1006-1015.
8. Liu KR, Peyman GA, Khoobehi B. Efficacy of liposome-bound amphotericin B for the treatment of experimental fungal endophthalmitis in rabbits. Invest Ophthalmol Vis Sci, 1989,30: 1527-1534.
9. Gupta SK, Dhingra N, Velpandian T, et al. Efficacy of fluconazole and liposome entrapped fluconazole for C. albicans induced experimental mycotic endophthalmitis in rabbit eyes. Acta Ophthalmol Scandi, 2000,78: 448-450.
10. Chinese source.
11. Chinese source.
12. Sullivan P, Clark WL, Kaiser PK. Bilateral endogenous endophthalmitis caused by HACEK microorganism. Am J Ophthalmol, 2002, 133:144-445.
13. Hatano H, Inoue K, Matoba H, et al. Endophthalmitis in Japan-a nationwide study with reference to type and etiology. Nippon Ganka Gakkai Zasshi, 1991,95:369-376.
14. Chinese source.
15. Pinna A, Carta F, Zanetti S, et al. Endogenous Rhodotorula minuta and Candida albicans endophthalmitis in an injecting drug user. Br J Ophthalmol, 2001, 85:759.
16. Thompson WS, Ruhsamen PE, Flynn HW Jr, et al. Endophthalmitis after penetrating trauma. Risk factors and visual acuity outcomes. Ophthalmology, 1995, 102: 1696-1701.
17. Essman TF, Flynn HW Jr, Smiddy WE, et al. Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis. Ophthalmic Surg Lasers, 1997, 28:185-194.
18. Chinese source.
19. Chinese source.
20. Kunimoto DY, Das T, Sharma S, et al. Microbiologic spectrum and susceptibility of isolates: part II. Posttraumatic endophthalmitis. Endophthalmitis Research Group. Am J Ophthalmol, 1999,128: 242-244.
21. Gupta A, Gupta V, Dogra MR, et al. Fungal endophthalmitis after a single intravenous administration of presumably contaminated dextrose infusion fluid. Retina, 2000, 20: 262-268.
22. Park SS, D'Amico DJ, Paton B, et al. Treatment of exogenous Candida endophthalmitis, in rabbits with oral fluconazole. Antimicrob Agents Chemother, 1995,39:958-963.
23. Chinese source.
24. Ostrosky-Zeichner L, Marr KA, Rex JH, et al. Amphotericin B: time for a new gold standard. Clin Infect Dis, 2003,37:415-425.
25. Klepser ME, Wolfe EJ, Jones RN, et al. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob Agents Chemother, 1997,41: 1392-1395.
26. Xie LX, Shi WY, Wang Z, et al. Prolongation of corneal allograft survival using cyclosporine in a polylactide-co-glycolide polymer. Cornea, 2001,20:748-752.
27. Xie L, Shi W, Wang Z, et al. Effect of a cyclosporine A delivery system in corneal transplantation. Chin Med J ( Engl), 2002, 115:110-113.
28. Xie L, Sun J, Yao Z. Heparin drug delivery system for prevention of posterior capsular opacification in rabbit eyes. Graefes Arch Clin Exp Ophthalmol, 2003, 241:309-313.
29. Pandey SK, Cochener B, Apple DJ, et al. Intracapsular ring sustained 5-fluorouracil delivery system for the prevention of posterior capsule opacification in rabbits: a histological study. J Cataract Refract Surg, 2002, 28: 139-148.
30. Yang CS, Khawly JA, Hainsworth DP, et al. An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch Ophthalmol, 1998, 116:69-77.
31. Jaffe GJ, Ben-Nun J, Guo H, et al. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology, 2000, 107:2024-2033.
32. Chinese source.
33. Chinese source.
34. Mijamoto H, Ogura Y, Hashizoe M, et al. Biodegradable scleral implant for intravitreal controlled release of fluconazole. Curr Eye Res, 1997,16:930-935.
35. Wingard LB Jr, Zuravleff JJ, Doft BH, et al. Intraocular distribution of intravitreally administered amphotericin B in normal and vitrectomized eyes. Invest Ophthalmol Vis Sci, 1989, 30: 2194-2189.
36. Tabbara KF, Jabarti AL. Hospital construction-associated outbreak of ocular aspergillosis after cataract surgery. Ophthalmology, 1998, 105:522-526.
37. Park SS, D'Amico DJ, Paton B, et al. Treatment of exogenous Candida, endophthalmitis in rabbits with oral fluconazole. Antimicrob Agents Chemother, 1995,39:958-963.
38. Chinese source.
39. Gulay A, Ergon C, Ozkutuk A, et al. Molecular epidemiologic surveillance and intensive care units. Mikrobiyol Bul, 2002,36: 309-316.
40. Chinese source.
41. Chinese source.